Monoclonal Antibodies and Antibody-Cytokine Platforms

• 4330 · PDF AWT038: Dual GDF15-IL-6 neutralization for cancer cachexia Fan Ye, Jianing Huang, Fang Huang, Botong Hua, Ella Li, Joyce Kwan, Jenny Jiang, Wen-Chin Huang, Frank Xiao, Hanna Lin, Lili Cheng, Ziyang Zhong
• 4331 ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, overcomes PD-1 resistance and enhances antitumor immunity with an accepted safety profile Cathy Wang, Lina Wang, Xue Wang, Xinchuan Dai, Qiuping Ye, Wilson Peng, Ziruo Wen, Lei Wang, Changwei Lv, Min Chen, Donghui Li, Qidong Hu, Bing Wan, Linda N. Liu
• 4332 AR166, a first-in-class PD-1xLAG-3xIL-2v tri-specific immunocytokine delivering Cis -acting IL-2v to overcome immune checkpoint inhibitor resistance Jaeho Song, Seon-mi Yu, Jae-Seok Lee, Jinkeol Mok, WooJeong Lee, Seo-Young Koo, Ye Rim Gu, Min-Young Park, Seoyun Yang, Juhan Yoon, Young Woo Park, Wooick Jang, Su-Hyung Park
• 4333 · PDF A universal pro-immunocytokine platform using a spatial hindrance strategy to overcome MHC resistance and enhance efficacy Chih-Hung Chuang, Shih-Ting Hong, Bo-Cheng Huang
• 4334 · PDF AR170, a novel PD-1xVEGFxIL-2v tri-specific immunocytokine to redefine next generation cancer immunotherapy Seon-Mi Yu, Jaeho Song, Juhan Yoon, Bum-Chan Park, Wooick Jang, Young woo Park, Chonghun Rhee, Jihye Yoon, Da-Mi Kim, Wanki Park, Yeung-chul Kim
• 4335 JMB2403, a potential best-in-class PD-1-dependent IL2Rbetagamma-targeting tri-specific antibody for safe and potent immunotherapy Chunyin Gu, Deyi Wang, Yan Wang, Fangfang Jia, Fu Zhou, Shun Chang, Yu Zhao, Linlin Liu, Huawei Zhang, Peipei Liu, Xiaodan Cao, Taylor B. Guo
• 4336 · PDF TGI-17a: A potential best-in-class PD-1/IL-2 alpha-bias cytokine fusion protein Guoshuai Cao, Yangyang Li, Yuwei Wu, Haoyu Sun, Zhigang Tian
• 4337 TGI-17b: A potential first-in-class PD-1/VEGF/IL-2 alpha-bias trispecific antibody and the potential next generation cornerstone for pan-cancer therapy Guoshuai Cao, Yangyang Li, Yuwei Wu, Haoyu Sun, Zhigang Tian
• 4338 · PDF Systematic discovery of attenuated IL-2 variants optimized for bispecific antibodies enabling targeted IL-2 delivery to PD-1 + T cells Jaehyeon Kim, Youngwoo Park, Sangheon Lee, Sooa Choi, Changho Jang, Sunha Yoon, Heebok Lee, Jaebong Yoon, Nayoung Lee, Hyenan Kim
• 4339 · PDF AI-designed PD-1/IL-18v bispecific antibody overcomes PD-1 resistance and drives potent antitumor responses in refractory models DongWon Park, Hyeonjin Cha, Kyesoo Cho, Yeorae Choi, Young-Hyun Han, Mirim Hong, Sohee Kwon, Myeong Sup Lee, Soyeon Oh, Seongchan Park, Taeyong Park, Jinsol Yang, Jonghun Won, Mooyoung Song, Chaok Seok, Yujin Lee, Chae-Rim Jung, Seung Goo Kang
• 4340 AZD6750, a CD8alpha-guided IL-2 immunocytokine effectively combines with rilvegostomig, a PD-1/TIGIT bispecific antibody, to enhance endogenous immunity Matthew J. Elder, Aidan H. Riley, Sin Lih Tan, Jerome Mastio, Bruno Frederico, Fabien Garcon, Hena Khalique, Georgina Bowyer, Paul Chariou, Nicholas M. Durham, Maria Broggi, Emily Hsiue, Simon Rodney, Jonathan B. Fitzgerald, Nadia Luheshi, Mark Cobbold, Saso Cemerski, Simon J. Dovedi
• 4341 A novel alphaPD-1/alphaVEGF/IL-21v tri-specific fusion protein exhibits potent antitumor efficacy beyond alphaPD-1/alphaVEGF bispecific therapy Suna Kim, Sunjung Cho, Hyojoo Bang, So Woon Kim, Yongjun Jung, Seokchan Kang, Suyoon Kim, Mi-Seong Kim, Jun-Eui Park, Young Jin Park, Sungyoub Jung
• 4342 · PDF MDNA113 is a masked conditionally activated tumor-targeted anti-PD1-IL-2 SK with superior safety and therapeutic properties Minh D. To, Rosemina Merchant, Aanchal Sharma, Fahar Merchant
• 4343 A novel anti-PD-1/IL-15 fusion protein JMT108 (SYS6090) with highly selective PD-1⁺ immune cell activation and potent anti-tumor efficacy Ke He, Yushan Kong, Jun Mu, Hongyan Wang, Yisha She, Yanfang Su, Yi Fan, Liping Song
• 4344 · PDF Interferon-alpha and PD-1 blockade mutually mask each other in a tumor-activated manner Shi-Wei Chao, Chih-Hung Chuang
• 4345 · PDF A multi-modal IL-2, SLC-3010, reprograms the tumor immune environment toward antitumor responses Junhyeok Heo, Daeun Kim, Geona Kim, Junyoung Lee, Sun Young Rha
• 4346 · PDF Tumor-localized monoclonal antibody targeting 4-1BB for superior safety and efficacy in cancer treatment Yun-Chi Lu, Yi-An Cheng, Tzu-Yi Liao
• 4347 · PDF A first-in-class bifunctional anti-TRPV6 antibody turns "cold" tumors "hot" Lindsay B. Alcaraz, Margaux Maurel, Tristan Mangeat, Vincent Roux-Portalez, Jessica Monnic, Marianne Le Gall, Anne Chevrel, Bernard Pau, Johanna Marines
• 4348 Anticancer activity of a humanized anti-VEGFR-1 monoclonal antibody and its derived antibody-drug conjugates targeting tumor cells and tumor-microenvironment components Pedro M. Lacal, Maria Grazia Atzori, Claudia Ceci, Federica Ruffini, Sonia Valentini, Lauretta Levati, Grazia Graziani
• 4349 · PDF Development of galectin-1 and galectin-7-specific inhibitors: Immunotherapy and molecular imaging in triple-negative breast cancer Rita Nehmé, David Chatenet, Nicolas Doucet, Yves St-Pierre
• 4350 · PDF pH-responsive PEGylated antibodies enables tumor-specific activation and attenuates immune-related adverse events Minji Ha, Torsha Ghosh, Sol Shin, Soyoung Son, Jae Hyung Park
• 4351 · PDF A sex-specific role of CD36 targeting therapy in colorectal cancer Huanyu Wang, Yi-Ru Yu, Yun-Han Lin, Jingying Zhou
• 4352 · PDF Therapeutic antibody inhibits target-mediated immune migration in advanced in-vitromodelofanimmune suppressive tumormicroenvironment Wouter Strijker, Iris Voskamp, Brian Duggan, Remko Van Vught, Luuk de Haan, Ward Celus, Linda Gijzen
• 4353 PHST001, a humanized anti-CD24 hIgG4 antibody, is effective against metastatic tumors and retains its anti-tumor activity in the presence of competing IgG Suzana A. Kahn, Joseane Sampaio, Douglas V. Faget, Rachel E. Brewer, Giovanni C. Forcina, Blacker Grace, Priyanka R. Malusare, Alexandria Beans, Seth D. Ludwig, John S. Burg, Jennifer Yinuo Cao, Raphaël F. Rousseau, Amira A. Barkal, Ravi Majeti, Irving L. Weissman, Roy L. Maute
• 4354 · PDF Harnessing VLPs and nanodiscs to unlock antibody discovery for challenging membrane proteins Hannah Flaherty Duncan, Shicheng Chen, Jia Cui, Tingxu Chen
• 4355 Cryo EM-based structural characterization of IMC-002, a next-generation anti-CD47 antibody with a unique binding site and biomarker candidates, supporting evidence of enhanced safety and efficacy Hyesun Lee, Jiyea Choi, HyeHyeon Jang, Heewook Shin, Jiyoung Yoon, Woochan Hwang, Sung Ho Kim, Heung Tae Kim
• 4356 · PDF Comprehensive characterization of DT-7012, a highly differentiated anti-CCR8 depleting antibody María Dolores García Fernández, Christel Franchet, Luc Baron, Solène Rose, Aurélie Janvier, Malaury Schappler, Lelièvre Hélène, Mélanie Frauli, Orphée Blanchard, Thibaut Brugat, Stephan Schann, Nathalie Lenne
• 4357 · PDF Novel monoclonal antibody kills lymphoma cells via LFA-1/ICAM-1 dependent, antibody-mediated cellular cytotoxicity Rui Xue Lee, Patrick W. Jaynes, Edward Kai-Hua Chow, Anand Devaprasath Jeyasekharan

在完整检索应用中浏览本分会场 →